Palayakotai Raghavan

Dr. Palayakotai Raghavan

Nanorx inc
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
PRPalayakotai Raghavan
Palayakotai Raghavan
Increasing outbreaks of new pathogenic viruses have promoted the exploration of novel alternatives to time‐consuming vaccines. Thus, it is necessary to develop a universal approach to halt the spread of new and unknown viruses as they are discovered. One such promising approach is to target lipid membranes, which are common to all viruses and bacteria. The ongoing severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic has reaffirmed the importance of interactions between the virus envelope and the host cell plasma membrane as a critical mechanism of infection. Metadichol®, a nanolipid emulsion of long‐chain alcohols, has been demonstrated as a strong candidate that inhibits the proliferation of SARS‐CoV‐2. Naturally derived substances, such as long‐chain saturated lipid alcohols, reduce viral infectivity, including that of coronaviruses (such as SARS‐CoV‐2) by modifying their lipid‐dependent attachment mechanism to human host cells. The receptor ACE2 mediates the entry of SARS‐CoV‐2 into the host cells, whereas the serine protease TMPRSS2 primes the viral S protein. In this study, Metadichol® was found to be 270 times more potent an inhibitor of TMPRSS2 (EC50 = 96 ng/mL) than camostat mesylate (EC50 = 26000 ng/mL). Additionally, it inhibits ACE with an EC50 of 71 ng/mL, but it is a very weak inhibitor of ACE2 at an EC50 of 31 μg/mL. Furthermore, the live viral assay performed in Caco‐2 cells revealed that Metadichol® inhibits SARS‐CoV‐2 replication at an EC90 of 0.16 μg/mL. Moreover, Metadichol® had an EC90 of 0.00037 μM, making it 2081 and 3371 times more potent than remdesivir (EC50 = 0.77 μM) and chloroquine (EC50 = 1.14 μM), respectively.

28 June 2022 in Research Square
Verified
Preprint
Open access
PDF file
PRPalayakotai Raghavan
Palayakotai Raghavan
The conversion of somatic cells back into induced pluripotent stem cells (iPSCs) or embryonic-like stem cells involves the introduction of four genes commonly called Yamanaka factors: SOX2, OCT4, KLF4, and c-MYC. One drawback is that these genes and the viral vectors used to introduce them into cells have the potential to cause cancer, and these iPSC lines are not clinically useful. Most instances of direct reprogramming have been achieved by the forced expression of defined factors using viral vectors. In this paper, we show that Metadichol® has the potential to generate iPSCs non-virally and may be helpful in clinical applications. Metadichol is a Nano formulation of long-chain alcohols derived from food. Quantitative real-time PCR (qRT-PCR) and western blotting showed that OCT4, SOX2, and NANOG are expressed when fibroblasts were treated with Metadichol at concentrations of one picogram to 100 nanograms. Reverse-transcription PCR (RT-PCR) resulted in OCT4, KLF4, NANOG, and SOX2 levels increased relative to controls by 4.01, 3.51 and 1.26, and 2.5 times, respectively. Such multifold increases were also seen in A549 cancer cell lines and in Colo-205 cells. Reprogramming human primary cancer cells remains a challenge. We present data that even primary cancer cells show increases in the four Yamanaka factors. Metadichol treatment of triple-negative primary breast cancer (HCAF-TNPBC) primary cancer cells led to increases in OKSM factors by 19.6, 8.07, 2.45, and 6.91 times in concentration ranges of 1 picogram to 100 nanograms. Metadichol induces the expression of Klotho, an antiaging gene, that curbs the expression of the TP53 gene, as this is a pre-requisite for reprogramming somatic cells into iPSCs. Metadichol also increases endogenous vitamin C levels, which is necessary for the efficient reprogramming of somatic cells into iPSCs. Metadichol an extract from food that is nontoxic, which opens the door to direct testing in humans with the potential for applications in stem cell therapy

6 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PRPalayakotai Raghavan
Palayakotai Raghavan
Background: Vitamin D binding protein (VDBP) is a precursor to macrophage activating factor (MAF) and regulates and controls innate immunity. Metadichol , a new nanoemulsion formulation that acts as an inverse agonist of the vitamin D receptor (VDR), was tested for its immunomodulatory effects on VDBP release in differentiated human monocytic cell lines Methods: THP-1 and U937 monocytic cell lines were differentiated with PMA (20 ng/ml) and stimulated with LPS. Various Metadichol concentrations (1 pg/ml to 100 ng/ml) were applied to cells for 48 hours. ELISA measured VDBP levels. Lipopolysaccharide stimulation significantly elevated VDBP release in both cell lines (10.19-fold in THP-1 cells: 117.01 ± 2.27 ng/ml; 12.03-fold in U937 cells: 222.56 ± 3.19 ng/ml vs. controls). Metadichol therapy altered VDBP release in a dose-dependent manner. Metadichol , at 100 ng/ml, significantly increased VDBP release (7.12-fold increase in THP-1: 81.73 ± 2.37 ng/ml; 8.36-fold increase in U937: 154.68 ± 3.19 ng/ml) while reducing LPS-induced inflammation. Metadichol shows dose-dependent immunomodulatory effects on VDBP release in human monocytic cells via VDR inverse agonism, outperforming traditional small molecule immunomodulators in immunological activation. The compound's VDR pathway modulation of VDBP levels without surpassing inflammatory thresholds suggests balanced immune response activation with potential therapeutic uses in immunological deficiency, cancer immunotherapy, and age-related immune decline.

26 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PRPalayakotai Raghavan
Palayakotai Raghavan
Background: The Gulo gene encodes L-gulonolactone oxidase, the terminal enzyme in the vitamin C biosynthesis pathway that is nonfunctional in humans and some other mammals. Metadichol, a nanoemulsion of long-chain alcohols, has demonstrated various biological activities. This study investigated the modulatory effects of Metadichol on Gulo gene expression across multiple mammalian species.Methods: Four mammalian cell lines representing different species were evaluated: rat (L6), mouse (C2C12), bovine (BT), and swine (ST) cells. Cells were treated with Metadichol at concentrations of 1 pg/ml, 100 pg/ml, one ng/ml, and 100 ng/ml for 24 hours. Total RNA was extracted using TRIzol reagent, and quantitative real-time PCR (qPCR) analysis was performed using species-specific Gulo gene primers. Gene expression was normalized to GAPDH and analyzed using the 2^-ΔΔCq method.Results: Metadichol treatment resulted in species-specific and dose-dependent upregulation of Gulo gene expression. Rat cells showed the highest response with 3.34-fold upregulation at 100 pg/ml, while showing downregulation at higher concentrations. Mouse cells demonstrated 2.01-fold upregulation at 100 pg/ml and 1.28-fold at 100 ng/ml. Bovine cells exhibited moderate upregulation of 1.61-fold and 1.21-fold at 100 pg/ml and 100 ng/ml, respectively. Swine cells showed optimal response at the lowest concentration (1 pg/ml) with 1.93-fold upregulation.Conclusions: Metadichol effectively stimulates Gulo gene expression across mammalian species in a dose- and species-dependent manner, with optimal concentrations varying between species. These findings suggest potential therapeutic applications for Metadichol in modulating vitamin C biosynthesis pathways and warrant further investigation into its mechanisms of action and clinical implications.

10 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PRPalayakotai Raghavan
Palayakotai Raghavan
Background: The 2025 Nobel Prize in Physiology or Medicine recognized the fundamental discovery of regulatory T cells and the FOXP3 gene as critical mediators of peripheral immune tolerance. This landmark workestablished a single-pathway mechanism for immune regulation Metadichol, a nanoemulsion of long-chainalcohols C26-C32, demonstrates pleiotropic immunomodulatory effects through coordinated regulation of masterregulator genes involved in T-cell function, B-cell development, NK cell cytotoxicity, metabolic reprogramming,and tumor suppression. Methods: We analyzed gene expression data from Metadichol-treated peripheral blood mononuclear cells PBMCs and resting fibroblasts across four concentrations 1 pg/mL, 100 pg/mL, 1 ng/mL, 100 ng/mL. A total of 36 master regulator genes were examined, including CD markers, transcription factors, and metabolic regulators. Comprehensive bioinformatic analysis included correlation network mapping, hierarchical clustering, and functional pathway enrichment to identify synergistic and antagonistic gene expression patterns. Results: Metadichol induced dramatic upregulation of key metabolic regulators including PPARγ 24.25-fold, PGC1α 11.08-fold, and tumor suppressor p53 9.61-fold, while coordinately modulating T-cell markers CD4 2.03-fold and CD8 2.15-fold. Correlation analysis revealed three strategic mechanisms: • Synergistic metabolic reprogramming through PPARγ-PGC1α co- activation r=0.991, • Immune balance optimization via antagonistic regulation of effector CDS versus suppressor FOXP3 functions, and • Dfferential cell-type regulation exemplified by the CDS-p53 antagonism r=-0.991. The upregulation of FOXP3 1.87-fold, the master regulator of regulatory T cells Tregs.

1 January 2025 in Medical Research Archives
Verified
Journal Article
Open access
PDF file
PRPalayakotai Raghavan
Palayakotai Raghavan
Nuclear receptors (NRs) are ligand-activated transcription factors that regulate the gene expression required for cellular reprogramming and pluripotency. This study examined the role of metadichol, a nanoemulsion of long-chain lipid alcohols (C26--C30), in modulating NR expression to increase the reprogramming of induced pluripotent stem cells (iPSCs). Using a nonviral method with metadichol at concentrations ranging from 1 pg/mL to 100 ng/mL, seven cell lines were evaluated, including human mesenchymal stem cells (HMSCs), normal human dermal fibroblasts (NHDFs), HEK293 cells, HeLa cells, THP-1 cells, triple-negative breast cancer cells, and primary prostate cancer cells. To assess the expression of 49 NRs, including estrogen-related receptor beta (NR3B2), nuclear receptor subfamily group A member 2 (NR5A2), and nuclear receptor subfamily 5 group member 1 (NR5A1), which can replace Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc) during iPSC generation, quantitative real-time polymerase chain reaction and western blot analyses were employed. Normal human dermal fibroblasts (NHDFs) and human mesenchymal stem cells strongly upregulated NR5A1 and NR5A2, which supported Oct4 replacement, and ERRβ, which facilitated Klf4 substitution. This upregulation made them highly suitable for NR-mediated reprogramming. Metadichol also induced the expression of pluripotency markers (e.g., alkaline phosphatase and Yamanaka factors), sirtuins, Fox head box protein O1 (FOXO1), Klotho, telomerase transcriptase (TERT) and insulin/beta cell formation, which suggests enhanced epigenetic remodeling and cell survival. This nonviral, scalable approach positions metadichol as a promising reagent for induced pluripotent stem cell (iPSC) differentiation in regenerative medicine, particularly for diabetes and oncology. These results suggest that metadichol could act as a universal nuclear receptor ligand, suggesting a comprehensive approach for efficient and safe induced pluripotent stem cell (iPSC) reprogramming.